trending Market Intelligence /marketintelligence/en/news-insights/trending/aylnn9uxvm_2kcctm1er_g2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Pernix Therapeutics closes acquisition of certain Orexigen assets

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Pernix Therapeutics closes acquisition of certain Orexigen assets

Nalpropion Pharmaceuticals Inc. completed the acquisition of certain assets from Orexigen Therapeutics Inc. for a reduced price of $73.5 million.

Bankrupt Orexigen Therapeutics previously agreed to sell nearly all of its assets to Nalpropion in a deal initially worth $75 million. The assets include worldwide rights to Orexigen's weight loss drug Contrave/Mysimba.

Nalpropion Pharmaceuticals is a special purpose vehicle formed by Pernix Therapeutics Holdings Inc., along with funds managed by investment management firms Highbridge Capital Management LLC and Whitebox Advisors LLC.

Morristown, N.J.-based Pernix Therapeutics will be responsible for the distribution of Contrave in the U.S. and the management of Nalpropion for an initial two-year period. The company will receive 5% of Nalpropion's net sales as management fee and reimbursement of certain shared services expenses.

The specialty pharmaceutical company was also granted two purchase options to buy up to 49.9% and 100% of Nalpropion within specific time periods and purchase prices.